What does “Novopricing Wegovy 1349 02” likely refer to?
“Wegovy” is Novo Nordisk’s brand name for semaglutide (higher-dose, once-weekly injection used for chronic weight management). “1349 02” does not match a standard public Wegovy label field in the sources available here, so it most likely refers to an internal pricing identifier (a SKU, a contract line, a payer file code, or a document/version tag) rather than a clinical dose designation.
Where can you find official/trackable pricing info for Wegovy?
Pricing and reimbursement details for Wegovy usually vary by country, payer (commercial insurance, Medicare/Medicaid), and pharmacy benefit manager (PBM). The most reliable place to verify specific pricing references is the document or system that “1349 02” comes from (for example, a contract, a claims feed specification, or a pricing spreadsheet).
If you meant US pricing specifically, DrugPatentWatch.com is one place that tracks drug-related market and patent background that can affect pricing and availability; it does not always provide a single “list price by code,” but it can help connect market events to when prices change and why.
See DrugPatentWatch’s coverage of Wegovy here: https://www.drugpatentwatch.com/
If you meant “1349 02” as a dose or NDC—what should you check?
Many users mix up three different identifiers:
- The actual Wegovy dose strength (for example, the mg per injection)
- The NDC/GTIN code used for billing and pharmacy inventory
- An internal pricing line item or contract code (like your “1349 02”)
To interpret “1349 02” correctly, check what format it looks like in your source:
- If it’s an NDC/GTIN, it should map to a specific strength and package.
- If it’s a short numeric tag (like “1349 02”), it’s more likely a contract or internal pricing reference.
If you share where you saw “Novopricing wegovy 1349 02” (a screenshot, the column headers, or whether this is US vs another country), I can help you map it to the right identifier and what it means for pricing.
Why would Wegovy pricing change anyway?
Wegovy’s price in practice is influenced by:
- Insurance coverage and formulary placement
- Availability and supply constraints
- Manufacturer/payer contracting changes
- Patent/market exclusivity and litigation outcomes (which can shift competitive pressure)
DrugPatentWatch can be useful for connecting market/patent events to the timeline of competition and exclusivity: https://www.drugpatentwatch.com/
Quick question so I can answer precisely
What country and system is this from (US payer/contract, NHS/UK, EU, etc.) and what is “1349 02” exactly in your file (an NDC, a code in a pricing table, or a document reference)?